Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 7/2016

Open Access 01-07-2016 | Review

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Authors: Axel S. Merseburger, Marie C. Hupe

Published in: Advances in Therapy | Issue 7/2016

Login to get access

Abstract

Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
3.
4.
Huggins C, Hodges CV. Studies on prostatic cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;19:293–7.
5.
Sobin LH, Gospodarowicz MK, Wittlekind C. TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 1999.
6.
Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314–22.PubMed
7.
Delahunt B, Egevad L, Grignon DJ, Srigley JR, Samaratunga H. Prostate cancer grading: recent developments and future directions. BJU Int. 2016;117(Suppl 4):7–8.CrossRefPubMed
8.
Ang M, Rajcic B, Foreman D, Moretti K, O’Callaghan ME. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL. BJU Int. 2016;117(Suppl 4):68–75.CrossRefPubMed
9.
10.
11.
Hoffman KE, Niu J, Shen Y, et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014;174:1450–9.CrossRefPubMedPubMedCentral
12.
Aizer AA, Paly JJ, Michaelson MD, et al. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014;10:107–12.CrossRefPubMed
13.
Gravis G, Boher JM, Fizazi K, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol. 2015;68:196–204.CrossRefPubMed
14.
Tunn UW, Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis. 2009;12:83–7.CrossRefPubMed
15.
Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29:757–65.CrossRefPubMed
16.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–8.CrossRefPubMed
17.
Ockrim J, el Lalani N, Abel P. Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Clin Pract Oncol. 2006;3:552–63.CrossRefPubMed
18.
Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437–45.CrossRefPubMed
19.
Merseburger AS, Scher HI, Bellmunt J, et al. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015;115:41–9.CrossRefPubMed
20.
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.CrossRefPubMed
21.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.CrossRefPubMed
22.
23.
Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM, European Treatment Practices G. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18:558–67.CrossRefPubMedPubMedCentral
24.
25.
26.
27.
28.
Ploussard G, Mongiat-Artus P. Triptorelin in the management of prostate cancer. Future Oncol. 2013;9:93–102.CrossRefPubMed
29.
Romero E, Velez de Mendizabal N, Cendros JM, et al. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharmacol Exp Ther. 2012;342:788–98.CrossRefPubMed
30.
Bouchot O, Soret JY, Jacqmin D, Lahlou N, Roger M, Blumberg J. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res. 1998;50:89–93.CrossRefPubMed
31.
Lebret T, Rouanne M, Hublarov O, et al. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Ther. Adv Urol. 2015;7:125–34.CrossRef
32.
Lee CR. Thrombosis and anti-thrombotic therapy. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Wintrobe’s clinical hematology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1993. p. 1533.
33.
Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021–4.CrossRefPubMed
34.
Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290–5.CrossRefPubMed
35.
Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J. 2013;7:E263–7.CrossRefPubMedPubMedCentral
36.
Bertaglia V, Tucci M, Fiori C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer. 2013;11(325–30):e1.PubMed
37.
Boccardo F, Decensi A, Guarneri D, et al. Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. Am J Clin Oncol. 1988;11(Suppl 2):S129–31.CrossRefPubMed
38.
Minkov NK, Zozikov BI, Yaneva Z, Uldry PA. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. Int Urol Nephrol. 2001;33:379–83.CrossRefPubMed
39.
Kuhn JM, Abourachid H, Brucher P, et al. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol. 1997;32:397–403.PubMed
40.
Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92:226–31.CrossRefPubMed
41.
Abbou CC, Lucas C, Leblanc V. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptorelin in patients with metastatic prostate cancer. Prog Urol. 1997;7:984–95.PubMed
42.
Martinez-Pineiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A, Triptocare Study Group. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU Int. 2014;114:608–16.CrossRefPubMed
43.
Botto H, Roupret M, Mathieu F, Richard F. Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer. Prog Urol. 2007;17:235–9.CrossRefPubMed
44.
de la Taille A, Martinez-Pineiro L, Cabri P, Houchard A, Schalken J. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy. BJU Int. 2016 (epub ahead of print).
45.
Kao CC, Chang YH, Wu T, et al. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer. J Chin Med Assoc. 2012;75:255–61.CrossRefPubMed
46.
Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res. 2004;62:252–8.CrossRefPubMed
47.
Mounedji N, Lundstrom EA, Purcea D, Grosgurin P, Porchet HC. Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer. J Clin Oncol. 2011;29(Suppl. 7):A162.
48.
Lehrer S, Stone NN, Droller MJ, Stock RG. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol. 2002;7:73–6.CrossRefPubMed
49.
Axcrona K, Aaltomaa S, da Silva CM, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721–8.CrossRefPubMed
50.
Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013;25:190–6.CrossRefPubMed
51.
Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90:321–8.CrossRefPubMed
52.
Gil T, Aoun F, Cabri P, Maisonobe P, van Velthoven R. A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer. Ther Adv Urol. 2015;7:116–24.CrossRefPubMedPubMedCentral
53.
Peltier A, Aoun F, De Ruyter V, Cabri P, Van Velthoven R. Triptorelin in the relief of lower urinary tract symptoms in advanced prostate cancer patients: the result study. Prostate Cancer. 2015;2015:978194.CrossRefPubMedPubMedCentral
54.
Shore ND, Sieber P, Schimke L, Perzin A, Olsen S. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer. Urol Nurs. 2013;33(236–44):48.
55.
Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V, Auddy G. Switching to a 6-monthly triptorelin formulation for prostate cancer (Pca) reduces patient-Nhs interactions and hospital resource use: real world evidence (Rwe) from project deserve (decapeptyl service evaluation). Value Health. 2015;18:A483.CrossRefPubMed
56.
Lebret T, Culine S, Davin JL, et al. Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. Aging Male. 2014;17:87–93.CrossRefPubMed
57.
Lebret T, Davin JL, Hennequin C, et al. Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study. Ther Adv Urol. 2014;6:205–14.CrossRefPubMedPubMedCentral
58.
Eisenhardt A, Schneider T, Scheithe K, Colling C, Heidenreich A, Studiengruppe T. Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX. Urologe A. 2016;55:176–83.CrossRefPubMed
59.
Evans SM, Nag N, Roder D, et al. Development of an international prostate cancer outcomes registry. BJU Int. 2016;117(Suppl 4):60–7.CrossRefPubMed
60.
Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res. 2011;3:201–9.CrossRefPubMedPubMedCentral
61.
Uttley L, Whyte S, Gomersall T, et al. Degarelix for treating advanced hormone-dependent prostate cancer: a single technology appraisal. Sheffield, UK: ScHARR, University of Sheffield; 2013.
62.
Merseburger AS, Hammerer P, Rozet F, et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015;33:1079–85.CrossRefPubMed
63.
64.
Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453–61.CrossRefPubMedPubMedCentral
65.
Brungs D, Chen J, Masson P, Epstein RJ. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:105–11.CrossRefPubMed
66.
Kunath F, Grobe HR, Rucker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014;6:CD009266.PubMed
67.
O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317–25.PubMedPubMedCentral
68.
Ryan CJ, Peng W, Kheoh T, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014;17:192–8.CrossRefPubMedPubMedCentral
69.
Sonpavde G, Attard G, Bellmunt J, et al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011;60:270–8.CrossRefPubMed
70.
71.
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.CrossRefPubMedPubMedCentral
72.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.CrossRefPubMed
73.
74.
Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67:23–9.CrossRefPubMed
75.
Caffo O, De Giorgi U, Fratino L, et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol. 2015;68:147–53.CrossRefPubMed
76.
Zhang T, Dhawan MS, Healy P, et al. Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13:392–9.CrossRefPubMed
77.
Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015;18:122–7.CrossRefPubMedPubMedCentral
78.
Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066–73.CrossRefPubMed
79.
Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12:451–9.CrossRefPubMed
80.
Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.CrossRefPubMed
81.
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–90.CrossRefPubMed
82.
83.
Metadata
Title
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Authors
Axel S. Merseburger
Marie C. Hupe
Publication date
01-07-2016
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2016
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0351-4

Other articles of this Issue 7/2016

Advances in Therapy 7/2016 Go to the issue

Original Research

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study

Review

Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)

Original Research

Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir

Original Research

Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis

Original Research

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Commentary

Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician’s Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits